Video

Immunotherapy revolutionizes frontline treatment in advanced RCC

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.

      Related Videos
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
      David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
      Fed Ghali, MD, on clinical outcomes in plasmacytoid urothelial carcinoma
      Fed Ghali, MD, on clinical outcomes in plasmacytoid urothelial carcinoma
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Ellen Cahill, MD, answers a question during a video interview
      Ellen Cahill, MD, on chaperone use for genitourinary exams
      Related Content
      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
      April 3rd 2025

      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

      Mehmet Asim Bilen, MD Hannah Clarke
      "The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
      female doctor talking with male patient
      December 22nd 2022

      Dr. Katherine Rotker on destigmatizing sexual health

      Urology Times staff
      "I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      Breakthrough Study in Image-Guided Prostate Cancer Treatment
      March 31st 2025

      Breakthrough Study in Image-Guided Prostate Cancer Treatment

      Yale School of Medicine
      Published OPTIMUM Trial results compares high-resolution micro-ultrasound with MRI when considering prostate biopsy.
      Subcutaneous nivolumab under review in EU for solid tumors
      March 31st 2025

      Subcutaneous nivolumab under review in EU for solid tumors

      Hannah Clarke
      The European Commission must issue a decision on the application on or by June 2, 2025.
      Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
      March 19th 2025

      Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

      Hannah Clarke
      "The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
      © 2025 MJH Life Sciences

      All rights reserved.